Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. EyePoint Pharmaceuticals, Inc.
483
•EyePoint Pharmaceuticals, Inc.•February 15, 2024

EyePoint Pharmaceuticals, Inc. – FDA 483, Feb 15, 2024

Record Details

An FDA inspection of EyePoint Pharmaceuticals, Inc., a human sterile drug manufacturer located in Watertown, MA, was conducted from February 6-15, 2024. This inspection, carried out under the Federal Food, Drug, and Cosmetic Act, identified significant deviations from current Good Manufacturing Practices (GMP). The agency issued a Form FDA 483 detailing seven observations, several of which were repeat findings from a previous 2021 inspection. Key issues centered on the firm's quality system and manufacturing controls for its YUTIQ 0.18 mg drug product. Specifically, the company failed to thoroughly investigate unexplained discrepancies, particularly concerning atypical drug release rates for YUTIQ, leading to the distribution of a lot associated with adverse events and therapeutic failures. Investigations for environmental monitoring excursions and recurrent facility issues, such as roof leaks and temperature fluctuations, were inadequate. Process control deficiencies were noted, including the absence of a continued process verification program and flawed visual inspection procedures lacking action levels and required investigations for product defects. The firm also did not adhere to its own Out of Trend procedures. Deviations from written production procedures were observed, such as the use of unapproved cleaning materials and incorrect equipment settings. Furthermore, equipment was not adequately cleaned or maintained, with evidence of rust and unknown residues, and a lack of cleaning validation for product-contact surfaces. Aseptic processing areas exhibited critical deficiencies, including unvalidated cleaning processes with incorrect disinfectant contact times, and operators failing to follow established gowning and personnel conduct procedures, increasing microbiological contamination risks. Finally, the firm demonstrated poor documentation practices, with inadequate control over critical CGMP records. EyePoint Pharmaceuticals, Inc. is required to address these observations by implementing comprehensive corrective and preventative actions to ensure compliance with regulatory standards and the quality and safety of its sterile drug products.

Company
EyePoint Pharmaceuticals, Inc.
Inspection date
February 15, 2024
Product type
drugs
Office
New England District Office
People
  • Sean R. Marcsisin (Senior Consumer Safety Officer - Pharmaceutical Quality)
  • Armen H. Youssoufian
  • Daniel L. Zheng (M.S., Consumer Safety Officer at FDA)
View Company Profile

ID · 98025cfc-32a8-40a8-bc43-3d513614aaf5

Other documents for EyePoint Pharmaceuticals, Inc.
  • WARNING_LETTER - 2024-02-15February 15, 2024
  • 483 - 2019-08-28August 28, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore EyePoint Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.